MindWalk Holdings (HYFT) Operating Leases (2023 - 2026)

MindWalk Holdings (HYFT) posted quarterly Operating Leases of $2.2 million for Q1 2026, down 3.44% quarter-over-quarter from $2.3 million in Q4 2025.

MindWalk Holdings (HYFT) Operating Leases (2023 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Operating Leases for 4 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $2.2 million; the TTM figure through Jan 2026 stood at $2.2 million (changed N/A YoY), while the FY2025 annual figure was $8.3 million, down 7.63% from the prior year.
Operating Leases retreated to $2.2 million in Q1 2026 per HYFT's latest filing, from $2.3 million in the prior quarter.
Across five years, Operating Leases topped out at $9.3 million in Q1 2024 and bottomed at $2.2 million in Q1 2026.
Historically, Operating Leases has averaged $6.1 million across 4 years, with a median of $8.1 million in 2025.
Annual changes were most pronounced in 2024 — Operating Leases jumped 96.6% — and 2025, when it sank 72.95%.
MindWalk Holdings' Operating Leases stood at $4.5 million in 2023, then jumped by 87.97% to $8.5 million in 2024, then tumbled by 72.95% to $2.3 million in 2025, then dropped by 3.44% to $2.2 million in 2026.
Business Quant data shows HYFT's Operating Leases at $2.2 million in Q1 2026, $2.3 million in Q4 2025, and $2.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data